In this article, we develop an ODE‐based model (MARM2.0) and a quantitative framework for analyzing “pathway rewiring” during the acquisition of adaptive resistance to RAF and MEK inhibitors in BRAFV600E melanoma. The gene discussed is MAP2K7; the disease is melanoma.